# The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction

Study · id `cardio:ct-nct05508035` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05508035](<https://clinicaltrials.gov/study/NCT05508035>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05508035

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 488 participants.

## Technical summary

Registry record NCT05508035. Randomized; double masking; primary purpose treatment. Start 2023-07-13 (actual); primary completion 2028-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 488 participants (planned count; ClinicalTrials.gov record NCT05508035, source copy `cardio:ctgov-nct05508035-2026-07-31`, retrieved 2026-10-26)
- Started: 2023-07-13 (actual) (ClinicalTrials.gov record NCT05508035, source copy `cardio:ctgov-nct05508035-2026-07-31`, retrieved 2026-10-26)
- Primary completion: 2028-08 (anticipated) (ClinicalTrials.gov record NCT05508035, source copy `cardio:ctgov-nct05508035-2026-07-31`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT05508035, source copy `cardio:ctgov-nct05508035-2026-07-31`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT05508035, source copy `cardio:ctgov-nct05508035-2026-07-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05508035-2026-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
- Acronym: CRACOVIA-HF
- Condition: Heart Failure With Moderately Reduced Ejection Fraction
- Intervention (Drug): Sacubitril / Valsartan
- Intervention (Drug): Ramipril
- Lead sponsor: John Paul II Hospital, Krakow
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Ramipril (`cardio:ramipril`)
- Registry lists this organization as the lead sponsor: John Paul II Hospital, Krakow (`cardio:org-john-paul-ii-hospital-krakow`)

## Provenance

Content hash: 87a7c8ee7e7ca685b5d40a504f8754d175fafba078b0cb663267325e31421ced
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
